Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 15/20 | 1.00 |
| ▸ | CTSB | P07858 | 3/20 | 1.00 |
| ▸ | CAPN9 | O14815 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CTSL | P07711 | 3/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CTSG | P08311 | 1/20 | 0.72 |
| ▸ | CTSK | P43235 | 2/20 | 0.66 |
| ▸ | CTSH | P09668 | 1/20 | 0.66 |
| ▸ | CTSS | P25774 | 1/20 | 0.66 |
| ▸ | CTSC | P53634 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E-64C SCHEMBL6041204 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL14067670 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL10750447 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL3281530 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL10933522 | 1.00 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL16982381 | 0.94 | CAPN1 (0.89) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL1807396 | 0.92 | CAPN1 (0.86) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL20643960 | 0.92 | CAPN1 (0.85) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL12653866 | 0.90 | CAPN1 (0.81) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL12904682 | 0.90 | CAPN1 (0.81) | CAPN1CTSBCAPN9MAPK1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60174777-A | — | — | None | — | — | JP | disclosed |
| US-20230408528-A1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) ANDCLEAVED HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-21 | — | — | US | disclosed |
| US-11826758-B2 | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20210322972-A1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | DYAX CORP. (US) | 2021-10-21 | — | — | US | disclosed |
| US-10870115-B2 | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation | DYAX CORP. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200237849-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2020-07-30 | — | — | US | disclosed |
| US-20190022641-A1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | DYAX CORP. (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190015472-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2019-01-17 | — | — | US | disclosed |
| US-10022418-B2 | Compositions and methods for treating beta-amyloid related diseases | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022418-B2 | Compositions and methods for treating beta-amyloid related diseases | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20110105603-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105603-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-1931656-B1 | NOVEL DRUGS FOR DEMENTIA | TERNANSKY ROBERT (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1931656-A1 | NOVEL DRUGS FOR DEMENTIA | Ternansky, Robert (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007038772-A1 | NOVEL DRUGS FOR DEMENTIA | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007038772-A1 | NOVEL DRUGS FOR DEMENTIA | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2007-04-05 | — | — | WO | disclosed |
| JP-S60174777-A | TRANS-EPOXYSUCCINIC ACID DERIVATIVE | TAISHO PHARMACEUT CO LTD | 1985-09-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105603-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885 |
| US-20080227806-A1 | Novel Drugs for Dementia | CTSS, PRSS1, CBS | CAPN1 273/4885CTSB 49/4885CAPN9 428/4885 |
| US-10022418-B2 | Compositions and methods for treating beta-amyloid related diseases | APP, BACE1, PTMS | CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885 |
| US-20200237849-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885 |
| US-20190015472-A1 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES | APP, BACE1, PTMS | CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.